
Place- Noida Dated: 24 May 2019



AstraZeneca Pharma India Limited

CIN: L24231KA1979PLC003563 Regd. Office: Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045. Tel.: +91 80 6774 8000. Web: www.astrazeneca.com/india

Statement of financial results for the quarter and year ended 31 March 2019

Rs. in lakhs (except for earnings per share							
SI. No.		3 months ended 31 March 2019	Corresponding 3 months ended in the previous year 31 March 2018	Year ended 31 March 2019	Previous year ended 31 March 2018		
	0.51 7 8 4 3 7 3 7 3 4	Refer Note 3	Refer Note 3	Audited	Audited		
1 2	Total income from operations Net profit / (loss) for the period from ordinary	19,631.49	15,306.48	74,457.95	58,423.68		
6	activities before tax Net profit / (loss) for the period from ordinary	847.32	1,405.68	7,266.35	4,380.01		
	activities after tax	982.38	322.14	5,444.07	2,591.48		
4	Total comprehensive income for the period after tax	1,132.86	, ,	5,384.02	2,363.49		
5	Equity Share Capital	500.00	500.00	500.00	500.00		
6	Reserves (excluding revaluation reserves as per balance sheet)	The state of the		29,580.50	24,193.18		
7	Basic and diluted earnings per share (of Rs 2 each)	3.93	1.29	21.78	10.37		

- 1 The above is an extract of the detailed format of Quarterly and Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Yearly Financial Results is available on the Stock Exchange websites. (www.nseindia.com, www.bseindia.com) and Company's website (www.astrazeneca.com/india).
- 2 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 3 The figures for the quarter ended 31 March, 2019 and 31 March, 2018 are the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the respective financial year which were subjected to review by the statutory auditors.

For AstraZeneca Pharma India Limited

Place: Bengaluru Date: 24 May, 2019

Gagandeep Singh Bedl Managing Director



Notes:

ROSSELL INDIA LIMITED

Regd. Office: Jindal Towers, Block 'B', 4th Floor, 21/1 A/3, Darga Road, Kolkata-700 017

CIN: L01132WB1994PLC063513 Website: www.rossellindia.com E-mail: corporate@rosselltea.com

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2019

Rs. in lakhi								s. in lakhs
		Standalone (Audited)				Consolidated(Audited)		
SI. No.	Particulars	Three months ended	Three months ended	Three months ended	Year ended	Year ended	Year ended (Note 3 below)	Year ended
		31,03,2019	31.12.2018	31.03.2018	31.03.2019	31.03.2018	31.03.2019	31.03.2018
1.	Total Income from Operations	4,728	8,354	3,740	24,868	19,852	A JE	19,852
	Net Profit (Loss) for the period	11.000	00		0	2000	-27	100
-	(before Tax, Exceptional and/or Extraordinary items)	(1,760)	267	(1,997)	50	(161)	=	(161)
3.	Net Profit (Loss) for the period before tax	35.5	Wash.					33 0 25
	(after Exceptional and/or Extraordinary items)	(1,771)	267	(1,997)	39	(161)	n in the	(161)
4.	Net Profit (Loss) for the period after tax	17 55	100	Dell	III-Y	1,510736-1	ALL MANY TO P	0.4
	(after Exceptional and/or Extraordinary items)	(1,514)	224	(1,472)	57	24	10 May 2	24
5.	Total Comprehensive Income for the period				10E-10	The same		W. 198
	[Comprising Profit (Loss) for the period (after tax)	The same	- 5		11 6			/E\
	and Other Comprehensive Income (after tax)]	(1,498)	216	(1,425)	50	(5)	10 121	(5) 734
6.	Equity Share Capital	734	734	734	734	734	STELL PROPERTY	
7.	Reserves (excluding Revaluation Reserve)	100			16,187	16,135	10 10 - 10	16,124
8.	Earnings Per Share (of Rs. 2 each)	1	100	100-701	(2)	100		
	(for continuing and discontinued operations) -	11 X	DM14	44.04	0.40	0.07	State of Land	0.07
34	- Basic (Rs.)	(4.13)	0,61	(4.01)	0.16	0.07	2	0.07
	- Diluted (Rs.)	(4.13)	0.61	(4.01)	0.16	0.07		0.07

HEALTHCARE GLOBAL ENTERPRISES LIMITED

Regd Off.: HCG Towers, No. B, P. Kalinga Rao Road, Sampangi Ram Nagar, Bengaluru – 560 027 CIN: L15200KA1998PLC023489

n: L13200N41996PL0023489 one: +91 80 4660 7700, Fax: +91 80 4660 7749 nall: investors@hcgoncology.com | Website: www.hcgel.com

EXTRACT OF THE CONSOLIDATED & STANDALONE RESULTS FOR THE QUARTER & YEAR ENDED 31st MARCH 2019



	Consolidated				Standalone				
ellio xerr Page 1 no	(Amount in Rs. Lakhs)				(Amount in Rs. Lakhs)				
Particulars	Quarter ended 31st March 2019	Quarter ended 31st March 2018	Full year ended 31st March 2019	Full year ended 31st March 2018	Quarter ended 31st March 2019	Quarter ended 31st March 2018	Full year ended 31st March 2019	Full year ended 31st March 2018	
Control of the Contro	Refer note 3		Audited		Refer note 3		Audited		
Total income from operations (net)	26,115,00	22,488,00	98,608,00	84,349,00	17,274,00	15,696,00	65,398.00	60,280_00	
Net profit/(ioss) for the period (before tax and exceptional items)	(818,00)	(224.00)	(3,338 00)	1,641.00	610,00	908,00	1,257,00	3,394,00	
Net profit/(loss) for the period (after tax and exceptional items)	(1,088,00)	(16,00)	(3,088 00)	1,641,00	303.00	765.50	725,00	2,490,00	
Net Profit/(loss) for the period attributable to equity share holders of the company	(872,00)	259 00	(2480,00)	2,052,00	303.00	765,50	725.00	2,490,00	
Total comprehensive income for the period (Comprising net profit and other comprehensive income after tax)	(854,00)	241,00	(2767,00)	2,034,00	295.00	746.00	313.00	2,470,00	
Equity share capital	8,792.00	8,690.00	8,792,00	8,690.00	8,792.00	8,690.00	8,792,00	8,690.00	
Earnings per share (of Rs,10 each) in Rs. Basic:	(0,99)	(0.30)	(2,82)	2.38	0,35	0.88	0.83	2.89	
Earnings per share (of Rs.10 each) in Rs. Diluted;	(0.99)	(0,30)	(2.82)	2.38	0.35	0,88	0,82	2.89	

- eviewed by the audit committee and approved by the board of directors at their meeting held on 23 May 2019.
- 2. The above Statement of Consolidated & Standalone Financial Results are based on respective Consolidated & Standalone financial statements, prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended, read with relevant rules issued thereunder in terms of the SEBI LODR, as modified by Circular No CIR/CFD/FAC/62/2016 dated July 5, 2016,
- statutory auditor is unqualified. The figures for the quarters ended 31 March 2019 and 31 March 2018 are the balancing figures between audited figures in respect of the full financial years and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which were subjected to limited review by the statutory auditor of the Company,
- 4. The above results are an extract of the detailed formal of quarterty and year ended results filed with BSE Ltd and National Stock Exchange of India Ltd as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the results are available on the websites of respective Stock Exchanges and the Company - https://hcgel.com/investors.

e statement of category wise utilisation of net proceeds from Initia	(Rs. in Lakhs)			
Category wise utilisation of net Proceeds from Initial Public Offer	Amount proposed to be utilised	Amount proposed to be utilised after reallocation	Actual Utilisation upto 31st March, 2019	
Purchase of medical equipment	4,220,00	258	258	
Investment in IT software,	3,019,00	2,981.00	2,981.00	*
Pre-payment of debt	14,704,00	14,704,00	14,704,00	
General Corporate Purposes	1,977,00	5,977.00	5,977,00	
	22 020 00	23 920 00	23.920.00	

- Rs. 3,962 lakhs from purchase of medical equipment and Rs. 38 lakhs from investment in IT software, services and hardware has been reallocated to General corporate purpose usage, as allowed by the 'Objects of the offer' section in the Prospectus of the Company for the Initial Public Offer
- * Includes Rs. 1,000 lakhs ear-marked for meeting payment commitments with regard to a contract for supply of IT softwares. 6. At the Board meeting held on 23 May 2019, the Board of Directors of the Company has approved the proposal for issuance of 710,526 equity shares of Rs. 10 per share at a price of Rs. 285 per share (inclusive of face value of Rs. 10 per share), on Preferential
- Allotment basis, to Dr., Gee Varghese ("Investor"), subject to the approval of the shareholders of the Company in the proposed Extra Ordinary General Meeting.

Date: May 23, 2019 Place: Bengaluru


For HealthCare Global Enterprises Limited

Chairman & CEO



AMBER ENTERPRISES INDIA LIMITED

Registered Office: C-1, Phase – II, Focal Point. Rajpura Town – 140 401. Punjab Corporate Office: Universal Trade Tower, 1st Floor, Sector -49, Sohna Road, Gurgaon – 122 018, Haryana E-mail; info@ambergroupindia com; Website: www.ambergroupindia.com Tel: +91 124 3923000; Fax: +91 124 3923016, 17; CIN: L28910PB1990PLC010265



16% **EBIDTA** 52% PAT

Extract of Audited Financial Results for the quarter and year ended 31 March, 2019